11th Oct 2006 07:00
International Medical Devices PLC11 October 2006 INTERNATIONAL MEDICAL DEVICES PRELIMINARY RESULTS FOR THE 12 MONTHS ENDED 31 AUGUST 2006 HIGHLIGHTS • Revenue of £3.8 million (2005: nil) • Operating Loss £222,000 before exceptional costs of £85,000 (2005: £323,000)At year end the Group had cash of £706,000 (2005: £363,000) • Three acquisitions completed during the year • £3.3 million raised in equity • All acquisitions produced positive operating profit contributions to the year end, and continue to trade profitably • Pro-forma revenue for the Group assuming 12 months full trading estimated at £10.7 million with estimated operating profits of £950,000 Commenting on the interim results, Lindsay Sanford, Chairman stated, 'I am happyto report IMD's acquisition strategy has proven successful leading to anestimated operating profit on a pro forma basis. The three earnings enhancingacquisitions have bedded down well and the company is benefiting greatly fromthe synergies and cost savings they have provided. The Company's continued focushas been to acquire a high quality product portfolio of established brands withproven management, and companies with track records of sales growth, solidmargins and profits. 'With product launches in the pipeline, the continuation of our acquisitionstrategy programme that will deliver continued growth and further synergies andcost savings, I look forward to IMD's future with confidence.' -Ends- Further Enquiries International Medical Devices Corporate Synergy Parkgreen CommunicationsChris Thomas Ian Rice Victoria ThomasCEO+44 203 008 4960 +44 117 933 0020 +44 207 493 3713 CHAIRMAN'S STATEMENT This has been a rewarding 12 months for International Medical Devices ("IMD")and in this period your Company has successfully concluded three acquisitions,establishing a growing and profitable medical devices trading house. The Company's continued focus has been to acquire a high quality productportfolio of established brands with proven management, and companies with trackrecords of sales growth, solid margins and profits. The three companies acquired - Meddis, Response Medical and EMS Medical -operate in different market sectors therefore enabling IMD to establish afocused divisional structure which will allow the targeting of non-discretionaryspend on medical devices by the NHS and the private sector. During the year ahead IMD will focus on the following four specific sectors: • Cardiorespiratory • Medical Consumables • Aged Care • Acute Care A recent Association of British Healthcare Institute (ABHI) survey of these foursectors, which account for approximately 50% of the UK medical devices market,has shown that they are seeing an 8-10% per annum market growth. This is dueto: • an ageing population • increasing Department of Health spending • rising demand for safety medical devices • an increasing emphasis on medical innovation within the NHS procurement process that is driven by the need for new products to meet the challenges facing the delivery of higher quality care IMD's ambition is to create a leading and profitable medical devicesdistribution business. UK healthcare spending is set to increase by more than7% per year up to and including 2008. The NHS budget for 2005 was a reported£84 billion which is equal to healthcare expenditure per capita of £1,436. Thisis bringing the UK closer to Germany and France in terms of per capita spend,and the government has stated that the 2007/2008 budget for the NHS will rise to£105 billion, a doubling of overall healthcare expenditure since 1997. IMD is well positioned to move forward by combining innovative IntellectualProperty ("IP") that is controlled and owned by the group, with the Company'sability to exploit its value in the market place by utilising the distributionnetwork that the acquisition programme has put in place. Today, IMD owns aportfolio of 'safe' needle technology and IP, and brands in devices includingsuction catheters ("Caretip" brands), ureteroscopy ("Peditrol"), plastic tubing("Tubicare"), head and neck products ("Breeze") and continence care ("Kylie" and"Kanga"). In the year ahead we intend to launch our safe needle, "Clip-on", and a range ofbeds for the hospital and elderly care markets. We will also continue ouracquisition programme and a detailed, investigative process is ongoing toidentify a number of target companies that meet our strict screening criteria;these include complimentary product ranges and brands that can deliver synergiesand cost savings, particularly in logistics and administration. IMD has achieved its first year growth objectives and has created theopportunities for an even better next 12 months. The Board wishes to thank allstaff and executives for their exceptional effort during the year and looksforward to providing future success to you as shareholders. The Board isconfident we will succeed. Lindsay C.S. SanfordChairman 10 October 2006 CHIEF EXECUTIVE'S REPORT In September 2005 IMD began the construction of a new, UK based medical devicedistribution business. Following the acquisition of Meddis Ltd ("Meddis"), inSeptember 2005, IMD successfully concluded the £6.3 million acquisition ofResponse Medical Group ("Response"). Response is a proven, profitable distributor with a strong, professionalmanagement team and I regard it as IMD's aircraft carrier. It is aroundResponse's business and its management that IMD is now looking to develop itsfuture business through a combination of acquisition and organic growth. The IMD business model is based both on acquisitions and the development of IPand the distribution rights acquired. By pursuing both routes, there is abalance of risk that will ensure shareholder value. Our approach to acquisitionsis to generate cross sales of products, cost savings via rationalisation ofwarehousing operations and administration functions and, with access to theacquired IP and distribution rights, to vigorously promote organic growth of the business. Business Strategy IMD's business strategy is focused on achieving three key objectives: 1. To establish and grow niche, technically orientated, medical devicedistribution capability in the UK across four target market sectors: - Cardiorespiratory - Medical Consumables - Aged Care - Acute Care 2. To establish channels to market the product portfolio by acquiringestablished profitable medical device distribution companies. 3. To continue to develop and exploit the IP and technology for 'safe'needles, with the objective of launching the "Clip-on" product range across keytarget markets by the last quarter of 2006. The challenge faced by the operational management team, led by John Butler, thefounder of Response, and Matthew Root, is to absorb the new acquisitions intothe four divisional structures with the benefits of making cost savings in thelogistics and administration areas. The procedures and logistics established by the group have allowed this processof absorption to happen. For example, the Meddis sales operations have merged,in capacity terms, with the Response team, whilst accounting functions from bothMeddis and EMS Medical have been moved to the Response head office at ChippingCampden. Divisional Structure 1. Cardiorespiratory The bulk of this division comprises of sales of defibrillators and ECGrecorders, in particular the Welch Allyn range of Propaq monitors. Response hasrecently been awarded exclusive UK rights to A&E departments and theatrerecovery for CPAP, a continuous airway pressure system from Respironics Inc.Other brands sold include Medicapteurs, Tyco and Medis. 2. Medical Consumables A key driver in the IMD business is the development within our product portfolioof a range of medical consumables. These include complimentary disposables soldin parallel with capital sales like electrodes, cables, BP cuffs, Sp02,defibrillator pads and paper. We are currently beginning to sell a range ofconsumables under our own 'Response Medical' brand. Response will launch the "Clip-on" safe needle product in Q4 2006. EMS Medical contributes its "Tubicare"range of disposables including catheters, eye shields, naso-gastric bile bags,utility clips, amniotic hooks and medical tubing. 3. Aged Care The Ypsomed range of "Penfine" diabetic needles are "selfcare health solutions",whilst the acquisition of EMS Medical provides a focus on the aged care sector.The range of products and brands sold in the division include a range ofwashable continence care protection ("Martex"), a foot operated irrigationsystem for ureteroscopy ("Peditrol"), tracheotomy and endotracheal care ("Breeze" head and neck), and continence care products ("Kylie" and "Kanga"). IMD intends to exploit the bed products developed by Eastland Medical SystemsLimited in Australia, and intends to launch them by 2007. Representing SalterLabs, IMD distributes an extensive range of specialist oxygen cannulae, oxygenmasks, nebulisers and oxygen supply tubing and accessories. 4. Acute Care Suction catheters for respiratory applications and wound drains represent amarket size of around £5 million for each product segment. IMD offers its ownbranded range of suction catheter "Caretip", and in-wound drains IMD representsProdukte fur die Medizin AG ("Pfm"), one of Germany's leading, independent salesspecialists for medical devices in the fields of pathology/histology, OP/anaesthesia, infusion therapy and interventional technologies. Other keyproducts in the acute care portfolio include a range of ophthalmic scalpels ("Feather") and a specialist respiratory product "Steritalc" from Novatech inFrance for the treatment of chronic pleurisies and malignant and spontaneouspneumothorax. Focus The focus on the four key market sectors outlined above allows IMD to exploitits portfolio of strong brands that are targeted at areas of the NHS whereprocurement practices are non-discretionary. Our ongoing aim is to continue tooffer the NHS a range of quality products and brands sought by clinicians. Oursales teams cover every hospital in the UK where they work alongside cliniciansto provide solutions and also to develop supply relationships with PASA ("NHSLogistics"). In October 2006, NHS Logistics will be outsourced to DHL. This contract willhave an impact on procurement of NHS supplies, particularly, I believe, wherePASA will look for better prices in commodity items. DHL will sub-contractprocurement outsourcing to Novation, a US based group-procurement organisation,in order to find better value for money contracts and engage more hospitals toreduce local purchasing contract agreements. This will offer IMD opportunitiesto act as a UK-wide "sales house". In September 2006, NHS logistics launched its"Home Delivery Continence Care Catalogue" (www.logistics.nhs.uk). EMS Medical,with its wide range of continence products occupies a significant part of thiscatalogue. Summary IMD has spent the last 12 months putting in place the structures to provide thecompany with growth areas for the future. These will be: 1. Further Acquisitions 2. Organic growth from acquired and existing products and brands 3. The exploitation of our IP via new product launches and achieving fast routes to markets 4. Acquisition of new distribution agreements from "major" principals as our reputation grows We continue to rely on our business partners both in the UK and overseas. Ihope they see IMD becoming an integral part of their sales solutions. Finally I would like to stress that it is individual commitment to a groupeffort that makes a team work, a company work, a society work, and acivilisation work. This is the ethic that I hope IMD will engineer amongstemployees, and which will carry the company further on its growth path. Christopher ThomasChief Executive Officer FINANCIAL REVIEW I am pleased to report that the financial performance of IMD, along with itsunderlying subsidiaries, has been very positive. All businesses acquired aretrading well and all have made positive operating profit contributions in theyear to 31 August 2006. There are many opportunities in the business sectors inwhich IMD operates, for growth both organically and through acquisition. Fund Raising and Acquisitions During the year to 31 August 2006, IMD successfully raised £3.3 million inequity. These funds have been utilised for the acquisition of the present IMDsubsidiaries, and for the development of business opportunities within the Groupand for working capital. Acquisition consideration for all three companies acquired took the form ofcash, shares, and performance related deferred share payments. The rationale isto incentivise the vendors to continue building the business, and in turnprofits, and to motivate them for longer term involvement with, and the successof, the Company. This formula has successfully been applied to all acquisitionsmade to date, and it is the Company's intention to continue with this approachwhere possible. Shares have in all cases to date been issued at a premium tothe market price at the time of the transaction, while deferred share paymentswill be made on the basis of the market price of the shares at the time paymentbecomes due. Capital reserves include expected future deferred consideration payable in theform of shares, amounting to £1,350,000, in accordance with InternationalFinancial Reporting Standard 3. Revenue The group achieved revenue of £3.8 million during the year to 31 August 2006.There are no comparative figures for revenue, as IMD had no sales in its ownright, nor had it made any acquisitions of trading companies, in the period to31 August 2005. Revenue reflects sales achieved by the companies acquired during the year, fromthe date of acquisition, to the year end. Therefore approximately elevenmonths' of trading has been included for Meddis, five months' trading forResponse, and one month's trading for EMS Medical. As a result, revenue isanticipated to be significantly greater for the year ending 31 August 2007, whenrevenue will include 12 months' sales for all three operating companies. Overseas revenue amounted to £40,000, arising from post acquisition sales by EMSMedical for one month to the year end. All other sales were within the UK. Operating margins on revenue averaged 36% for the year, and these levels ofmargins are set to continue. Operating Profit IMD incurred an Operating Loss before exceptional items for the year, amountingto £222,000 (2005: Loss £323,000). This result reflects full year centraloverheads for IMD, but part year operating profit contributions from theoperating subsidiaries acquired during the year, as noted above. All threeoperating companies however produced positive operating profit contributionsfollowing the date of acquisition to the year end. In addition, the Group incurred an exceptional cost of £85,000 arising from therestructuring of one acquisition, resulting in the closure of a warehouse andadministration centre, with the operations being consolidated into the ChippingCampden location. This closure will result in direct savings, the benefits ofwhich will be reflected in next year's operating profit. With no corporation tax payable in the period, the resultant loss after tax forthe period amounted to £360,000. Pro-forma revenue and operating profit Following the acquisition of the three companies during the year ended 31 August2006, the pro-forma revenue for the Group, assuming 12 months full trading ofthese companies, are estimated to be £10.7 million, with an estimated operatingprofit of £950,000. These figures are unaudited and do not form part of thefinancial statements. Cash and Net Debt The Group had cash of £706,000 at the year end (2005: £363,000). This is beforeshort term loans of £350,000 and long term loans of £1,300,000. Therefore netdebt amounts to £944,000 (2005: £Nil). The long term debt was taken on as partof the Response acquisition and is repayable over a four year term. The shortterm debt also formed part of assets acquired. Gearing, net of cash balances,is 6.0% of net assets (2005:Nil%), and is considered prudent relative tooperational cashflow generation. Net finance cost for the period amounted to£53,000 (2005: £Nil). Working Capital Medical devices distribution businesses rely on having inventory available, inmost cases, for immediate delivery. The Group is focusing on keeping inventorylevels to a minimum, but without adversely affecting sales. Inventory at 31August 2006 amounted to £1,719,000. Goodwill IMD has Goodwill on the Balance Sheet amounting to £8,674,000 (2005 £Nil),including purchased Goodwill. This Goodwill arises directly from the differencebetween the consideration paid for the acquisition of companies during the year,and the net assets acquired. The nature of distribution companies is that NetAssets acquired are likely to be small in relation to the company'sprofitability, as the business by its very nature is not significantly capitalintensive. Goodwill includes expected future deferred consideration payable inthe form of shares, in accordance with International Financial ReportingStandard 3. International Financial Reporting Standards IMD has adopted International Financial Reporting Standards, even though thereis currently no requirement to do so. This approach has been adopted on thebasis of good practice. Restatement of 2005 comparatives based on InternationalFinancial Reporting Standards does not result in any changes to the figuresreported. Dividends IMD is not declaring a dividend for the year. Mindful of shareholder wishes, aprogressive dividend policy will be adopted in future, when the Board ofDirectors considers it appropriate in relation to the Group's financialposition. Taxation There is no corporation tax charge for the year. Tax losses, subject to HMRevenue & Customs agreement, of £600,000 are available in IMD, which will beavailable for future offset. Given the short history of IMD, we are pleased with the financial performance ofthe Group, and have every confidence for the future. Mike AchesonFinance Director CONSOLIDATED INCOME STATEMENTFOR THE PERIOD ENDED 31 AUGUST 2006 Group _____________________________ Year ended 13 month period ended 31 Aug 2006 31 Aug 2005 £'000 £'000 Revenue 3,817 - Cost of sales (2,443) - _______ _______ Gross profit 1,374 - Distribution expenses (460) -Administration expenses (1,136) (323) _______ _______ Operating loss before restructure costs (222) (323)Restructure costs (85) - _______ _______ Operating Loss (307) (323) Finance costs (70) -Finance income 17 6 _______ _______ Loss before tax (360) (317)Taxation - - _______ _______ Loss for the year (360) (317) _______ _______ Loss per share Basic and Diluted £(0.0021) £(0.0125) There were no other gains or losses other than those recognised in the income statement. All activitiesrelate to continuing activities. BALANCE SHEETAS AT 31 AUGUST 2006 Group Company _______________________________________________ 2006 2005 2006 2005 £'000 £'000 £'000 £'000AssetsNon-current assetsGoodwill 8,674 - - -Other Intangible Assets 8,479 7,953 8,001 7,953Property, plant and equipment 233 - - -Investments in subsidiaries - - 8,494 - ________ ________ ________ ________ 17,386 7,953 16,495 7,953Current Assets Inventories 1,719 - - -Trade receivables 1,276 - - -Other receivables 290 128 - 128Intercompany loan - - 188 -Cash and cash equivalents 706 362 175 363 ________ ________ ________ ________ 3,991 491 363 491 ________ ________ ________ ________ Total assets 21,377 8,444 16,858 8,444 ________ ________ ________ ________Equity and liabilitiesEquity attributable to equityholders of the parentShare capital 2,489 1,245 2,489 1,245Share premium 12,499 7,251 12,499 7,251Capital reserves 1,350 - 1,350 -Retained earnings (677) (317) (862) (317) ________ ________ ________ ________ 15,661 8,179 15,476 8,178 Non-current liabilitiesBank loans 1,300 - - -Convertible loan notes 250 - 250 -Other non-current liabilities 444 - - - ________ ________ ________ ________ 1,994 - 250 -Current liabilitiesTrade and other payables 3,122 265 349 265Intercompany loan - - 533 -Convertible loan notes 250 - 250 -Bank loans 350 - - - ________ ________ ________ ________ Total liabilities 5,716 265 1,382 265 ________ ________ ________ ________ Total equity and liabilities 21,377 8,444 16,858 8,444 ________ ________ ________ ________ CONSOLIDATED CASH FLOW STATEMENTFOR THE YEAR ENDED 31 AUGUST 2006 Year ended 13 month period ended 31 Aug 2006 31 Aug 2005 £'000 £'000Cash flows from operating activitiesLoss from operations (307) (323) Adjustments for:Depreciation of property, plant and equipment 45 - _________ _________ Operating cash flows before movement in working capital (262) (323) (Increase) in inventories (316) (128)Decrease in receivables 892 -(Decrease)/ Increase in payables (320) 265Tax paid (80) - _________ _________ Cash generated from operations (86) (186)Interest paid (70) - _________ _________ Net cash from used in operating activities (156) (186) Cash flows from investing activitiesInterest received 17 6Acquisition of Intellectual Property rights (44) (150)Acquisition of Meddis Ltd net of cash acquired (170) -Acquisition of Response Holdings Ltd net of cash acquired (1,890) -Acquisition of EMS Medical Ltd net of cash acquired (374) - _________ _________ Net cash (used in) investment activities (2,461) (144) Cash flows from financing activitiesNet proceeds on issues of shares 2,815 693Net borrowings 145 - _________ _________ Net cash from financing activities 2,960 693Net increase in cash and cash equivalents 343 363 Cash and cash equivalents at beginning of period 363 - _________ _________ Cash and cash equivalents at end of year 706 363 _________ _________ Bank balances and cash 706 363 _________ _________ NOTES: 1. The financial information in this announcement does not constitutestatutory accounts as defined in section 240 of the Companies Act 1985. Theauditors have given an unqualified report that does not contain any statementunder section 237(2) or (3) of the Companies Act 1985, on the statutory accountsfor the year ended 31 August 2006. 2. Copies of the Company's Report and Accounts will be sent toshareholders shortly and will be available at the registered office of theCompany: 10 Orange Street, London, WC2H 7DQ. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Intelliam Ai